Oclaro Inc (OCLR) Jumps 8.59% on January 12

Equities Staff |

Oclaro Inc (OCLR) was among the biggest gainers on the Russell 2000 for Tuesday January 12 as the stock popped 8.59% to $3.54, representing a gain of $0.28 per share. Some 2.46 million shares traded hands on 8,855 trades, compared with an average daily volume of 1.31 million shares out of a total float of 110.76 million. The stock opened at $3.30 and traded with an intraday range of $3.54 to $3.28.

After today's gains, Oclaro Inc reached a market cap of $392.08 million. Oclaro Inc has had a trading range between $3.74 and $1.40 over the last year, and it had a 50-day SMA of $3.38 and a 200-day SMA of $2.62.

Oclaro Inc is engaged in providing laser and optical components, modules and subsystems for the telecommunication and data communication equipment companies.

Oclaro Inc is based out of San Jose, CA and has some 1,233 employees. Its CEO is Gregory P. Dougherty.

For a complete fundamental analysis analysis of Oclaro Inc, check out Equities.com’s Stock Valuation Analysis report for OCLR. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Snapchat is the fastest way to share a moment with friends. The mobile app, allows users to not only share photos with friends but also control how long they can…

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…